The trial is sponsored by Collaborative Medicinal Development Pty Limited and aims to evaluate the efficacy and tolerability of Cu(II)ATSM in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). The ALS market is characterized by limited treatment options, primarily dominated by riluzole and edaravone, which highlights a significant unmet need for novel therapies. Successful outcomes from this trial could position Cu(II)ATSM as a competitive therapeutic option, potentially expanding the treatment landscape for ALS/MND. The estimated enrollment of 80 patients suggests a focused study, which may facilitate quicker data analysis and market entry if successful. However, the overall status of the trial remains 'UNKNOWN' as of the last update, necessitating close monitoring of recruitment and results.